Celsion Corporation (NASDAQ: CLSN) and Relypsa (NASDAQ:RLYP) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.
This table compares Celsion Corporation and Relypsa’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Celsion Corporation and Relypsa’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Celsion Corporation||$500,000.00||94.95||-$22.05 million||($5.83)||-0.49|
Relypsa has higher revenue, but lower earnings than Celsion Corporation. Relypsa is trading at a lower price-to-earnings ratio than Celsion Corporation, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
6.4% of Celsion Corporation shares are held by institutional investors. 3.8% of Celsion Corporation shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Celsion Corporation and Relypsa, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Celsion Corporation currently has a consensus price target of $14.50, suggesting a potential upside of 406.99%. Given Celsion Corporation’s higher probable upside, research analysts plainly believe Celsion Corporation is more favorable than Relypsa.
Celsion Corporation beats Relypsa on 6 of the 9 factors compared between the two stocks.
Celsion Corporation Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
Relypsa Company Profile
Relypsa, Inc. is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company’s technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address. Its polymers are non-absorbed, meaning they act within the gastrointestinal tract and do not get absorbed into the bloodstream or other parts of the body. Its polymer technology may be able to address many health conditions in need of viable treatment options. Its VELTASSA (patiromer) for oral suspension is a commercialized medicine resulting from its polymer technology platform. VELTASSA is a potassium binder approved for the treatment of hyperkalemia. Available in powder form, VELTASSA is mixed with water and taken daily. VELTASSA’s spherical beads bind to potassium in exchange for calcium, primarily in the colon.
Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.